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Summary Current reports suggest serum S100 as a prognostic marker for disease progression in advanced malignant melanoma. In this
study, we assessed serum levels of S100 and multiple clinical factors in relation to overall survival in 99 patients with metastatic malignant
melanoma seen at our institution between May 1990 and April 1996. For statistical analysis, we used both univariate and multivariate Cox
proportional-hazards models. Elevated serum levels of S100 correlated with poor outcome in metastatic malignant melanoma (P < 0.0001),
univariate analysis). Upon multivariate analysis, however, S100 added no information to known clinical prognostic parameters.
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Malignant melanoma, in humans, belongs to those tumours whose
incidence has been rising steadyily over the past few decades
(Grin-Jorgensen et al, 1992; Glass and Hoover, 1993). Once
disseminated, it is mostly refractory to conventional treatment
modalities, and survival rarely exceeds 8 months in patients devel-
oping distant metastases (Legha, 1989; Koh, 1991). However,
variability ofsurvival supports the hypothesis ofmetastatic malig-
nant melanoma as a biologically heterogeneous tumour entity. So
far, few preclinical parameters have been established toward
prediction ofthe malignant potential ofadvanced melanoma.
Protein SI00 is an acidic calcium-binding protein with a molec-
ular weight of 21 000 Da, consisting of two isomeric subunits
called a and 13 (Dannies et al, 1969; Isobe et al, 1981). Expression
of S100 is found in malignant melanoma, and elevated serum
levels of S100 have been described in metastatic malignant
melanoma (Gaynor et al, 1981; Fagnart et al, 1988). Previously,
increased serum S100 has been identified as a marker of disease
progression in metastatic malignant melanoma (Guo et al, 1995).
Therefore, serum S100 might be a useful adjunct in the clinical
staging and monitoring ofmetastatic malignant melanoma.
The aim of this study was to evaluate the prognostic relevance
ofpretreatment serum SI 00 and ofmultiple clinical parameters in
relation to overall survival in 99 patients with metastatic malignant
melanoma using univariate and multivariate Cox proportional-
hazards models.
MATERIALS AND METHODS
Patients and collection of samples
This study was approved by the institutional review board of the
Medizinische Hochschule Hannover. Written informed consent was
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obtained from all patients before entry into the study. At that time,
we obtained samples of peripheral blood from 99 patients with
metastatic malignant melanoma, seen at our institution since May
1990. Sera were frozen at -70°C until analysis. All patients had a
Kamofsky performance status .70%, and presented with histologi-
cally confirmed metastatic malignant melanoma (21 nodular, 16
amelanotic, 23 superficial spreading, three acral lentiginous, five
uveal and 31 unclassified). All patients presented with clinically
progressive disease as demonstrated by standard radiographic
procedures. Patients received chemoimmunotherapy containing
subcutaneous interleukin 2, interferon ct2a and intravenous plat-
inum, dacarbazine with or without carmustine (Atzpodien et al,
1995); treatment was continued until further disease progression
occurred. Response to therapy was evaluated on an intention-to-
treat basis and was assessed according to WHO criteria.
Immunoradiometric assay for serum S100
Levels of serum S100 were measured using a monoclonal two-
sided immunoradiometric sandwich assay (kindly provided by
Byk-Sangtec Diagnostics, Dietzenbach, Germany). The mono-
clonal antibodies detect the 1313 and a13 S100 dimer. All analyses
were performed in triplicate strictly according to the procedures
recommended by the manufacturers and samples were analysed at
a dilution resulting in measured concentrations within the range of
the standard curves.
Statistical analysis
The statistical end point in our analysis was overall survival from
time of entry into the study. Univariate hazard ratios with 95%
confidence intervals were calculated using the Cox proportional-
hazards model (Cox, 1972). Clinical parameters and S100 serum
levels were tested as dichotomized prognostic variables. For age,
time since tumour progression, time since tumour diagnosis,
erythrocyte sedimentation rate (ESR), neutrophil count, haemo-
globin, and serum SI00, Kaplan-Meier estimates were performed
defining the best cut-off value as the value that best discriminates
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Table 1 Factors related to survival in metastatic malignant melanoma (univariate analysis)
Hazard ratio
Variables Categories compareda (95% confidence P-valueb
interval)
Sex Female vs male 1.06 (0.84-1.33) 0.65
Age (years) < 60 vs a 60 1.03 (0.81-1.32) 0.78
Histology Cutaneous vs uveal 0.40 (0.14-1.10) 0.08
Time since tumour < 10 vs a 10 1.24 (0.94-1.62) 0.13
progression (months)
Time since tumour < 24 vs a 24 0.96 (0.53-1.73) 0.90
diagnosis (months)
Liver metastases Absent vs present 0.71 (0.55-0.90) <0.01
Lung metastases Absent vs present 0.87 (0.69-1.10) 0.24
Brain metastases Absent vs present 0.65 (0.39-1.09) 0.10
Bone metastases Absent vs present 0.89 (0.59-1.36) 0.60
Metastatic sites One site vs more than one site 0.75 (0.60-0.95) 0.02
ESR (mm h-1) < 50 vs a 50 0.66 (0.51-0.87) < 0.01
CRP (mg 1-') <8 vs a 8 0.76 (0.60-0.96) 0.02
LDH (U I-') < 240 vs a 240 0.54 (0.42-0.68) < 0.001
Neutrophil count (cells RI-1) < 6000 vs a 6000 0.92 (0.69-1.21) 0.54
Haemoglobin (g dl-1) < 10 vs a 10 1.18 (0.80-1.74) 0.41
Serum S100 ([tg 1-1) <3 vs a 3 0.61 (0.46-0.79) <0.001
aFor each variable, the prognostic significance of the first category listed was assessed by comparing that category with the reference
category (the second category listed). bFor the comparison of the hazard ratio shown with a hazard ratio of 1.0 (as postulated by the null
hypothesis).
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Figure Serum S100 and cumulative survival in 99 patients
malignant melanoma (Kaplan-Meier estimate). Solid line, lo
of S100 (< 3 9tg I-'); dashed line, elevated serum levels of S
P-value was determined by the log-rank test. Tick marks rep
for whom data were censored
between poor and good overall survival; differ(
groups in overall survival were tested with the
(Kaplan and Meier, 1958). For lactate dehydrogen
C-reactive protein (CRP), the institutional upper
were chosen as cut-off (< 240 U 1-1 and < 8 mg 1-
The simultaneous prognostic effect of various fact
mined in a multivariate analysis using the Cox
hazards model (forward selection of variables). T
association between two dichotomous variables w(
square test, or a two-tailed Fisher's exact test wi
values being compared was less than 5.
RESULTS
We assessed the prognostic significance ofvarious clinical factors
and of serum S100 in patients with advanced malignant
melanoma. The mean follow-up interval was 29 months (range
3-71 months) for the surviving cohort; median survival of all
patients entering the study was 10 months.
First, we calculated univariate hazard ratios with the Cox
proportional-hazards model (Table 1). Thus, LDH, ESR, CRP, the
presence of liver metastases and the number of metastatic sites
showed prognostic significance as to overall survival. Elevated
serum levels of S100 (2 3 .tg 1-1) were detected in 22 patients and
were associated with an unfavourable outcome; median survival in
these patients was 6 months, whereas patients with serum S100
P<0.001 below 3 jtg 1-' (n = 77) achieved a median survival of 13 months
60 72 (P <0.001; Figure 1). Elevated serum LDH (.240 U 1-) and
increased ESR (. 50 mm h-1) also achieved high prognostic signif-
icance upon multivariate analysis (P < 0.001, P < 0.01), with a
with metastatic median survival of 5 and 6 months in patients without, and 16 and
w serum levels 11 months in patients with, increased LDH and ESR respectively.
100 (a 3 tg 1-1). The presence of liver metastases was an important prognostic
zresent patients
factor when examined by single-factor analysis (P < 0.01). The
median survival for patients with liver metastases was 6 months,
compared with 11 months for patients without liver metastases. It
ences between is notable that brain, lung and bone metastases were not associated
log-rank test with a poorer clinical outcome. Patients with a single metastasis
ase (LDH) and had longer survivals than patients with metastases at two or more
normal limits sites (P = 0.02). The median survival was 13 months for patients
' respectively), with one metastatic site, and 7 months for those with more than
tors was deter- one metastatic site. Time since tumour progression and since
proportional- tumour diagnosis were not rendered statistically significant in
bo evaluate the predicting overall survival (P = 0.13; P = 0.90).
e used the chi- Multivariate analysis of survival was undertaken examining the
hen one of the simultaneous effect of factors that were significant on univariate
analysis. Although serum SiO, ESR, CRP and the number of
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Table 2 Patient characteristics of 99 patients with metastatic malignant
melanoma to S100
Variables Total Low S100 Elevated S100 P-valuea
(<3 ,ug I ') (a 3 [tg 1-1)
Sex
Male 61 48 13 0.78
Female 38 29 9
Age (years)
< 60 65 48 17 0.19
a60 34 29 5
ESR
< 50 (mm h-1) 78 67 11 < 0.001
> 50 (mm h-1) 21 10 11
CRP
<8 (mg 1-1) 58 48 10 0.16
8(mgl-1) 41 29 12
LDH
<240 (U1-1) 58 55 3 <0.001
> 240 (U -1) 41 22 19
Liver metastases
Absent 70 57 13 0.17
Present 29 20 9
Metastatic sites
One site 52 44 8 0.09
More than one site 47 33 14
aBy chi-square test, or by a two-tailed Fisher's exact test when one of the
values being compared was < 5.
metastatic sites were not rendered independent by multivariate
analysis, serum LDH (P < 0.0001) and the presence ofliver metas-
tases (P = 0.04) were found to be significant. The hazard ratio was
0.55 (95% CI 0.43-0.70) for serum LDH and 0.76 (95% CI
0.59-0.98) for liver metastases; thus, both factors were associated
with a survival benefit.
Elevated serum levels ofS100 were independent ofsex, age, the
presence of liver metastases and the number of metastatic sites
but correlated significantly with increased serum levels of LDH
(P < 0.001), and ESR (P < 0.001) (Table 2).
DISCUSSION
Serum 8100 was first described to be elevated in metastatic malig-
nant melanoma by Fagnart et al (1988). Serum S100 in the sera of
melanoma patients has been thought to be, in part, derived from
tumour tissue, as evidenced by the immunohistochemical detec-
tion of the S100 protein in malignant melanoma tissue (Gaynor
et al, 1981). More recently, in a preliminary analysis, serum
S100 was shown to correlate with the clinical stage of the tumour
(Guo et al, 1995).
In the current study, we found that elevated serum S100 is a
prognostic indicator of overall survival in patients with metastatic
malignant melanoma. By univariate analysis, the most significant
prognostic variables were (a) LDH, (b) S100, (c) erythrocyte sedi-
mentation rate, and (d) liver metastases. Upon multivariate
analysis, LDH (P < 0.0001) and the presence of liver metastases
(P = 0.04) were the dominant independent prognostic variables.
S100 lost its statistical significance upon addition of LDH in the
proposed multivariate Cox model, indicating a link between these
two prognostic markers.
Serum LDH has been identified as a prognostic parameter in
association with tumour burden (Heimdahl et al, 1989; Sirott et al,
1993). In this study, 41% of patients had elevated serum levels of
LDH, but only 29% had confirmed liver metastases. Moreover,
serum LDH and the presence ofliver metastases were independent
prognostic markers upon multivariate analysis. Brain, lung and
bone metastases were not associated with a shorter survival; most
patients with brain metastases received radiation therapy to the
brain, which may have resulted in a long enough survival to allow
other factors to be more powerful in predicting the clinical course
ofdisease. In the present study, the number ofmetastatic sites was
not of independent significance. This may be explained in part by
the inclusion of serum LDH in this study, which achieved statis-
tical significance as a more accurate marker of tumour burden.
Erythrocyte sedimentation rate, which is a known unspecific
marker in various human malignancies, did not reach statistical
independence.
Several other preclinical parameters have been reported to corre-
late with disease progression in melanoma, including cytogenetic
abnormalities, DNA ploidy and S-phase fraction, the expression of
metastasis associated gene products, elevated serum levels ofsoluble
adhesion molecules and the detection ofcirculating melanoma cells
in peripheral blood using reverse transcription-polymerase chain
reaction (RT-PCR) for tyrosinase messenger RNA (Trent et al,
1990; Smith et al, 1991; Xerri et al, 1994; Karlsson et al, 1996;
Kunter et al, 1996). These parameters could reflect increase in the
total tumour mass, recurrence ofthe disease orthe presence ofoccult
melanoma. Although it remains to be clarified which prognostic
markers should be assayed to estimate melanoma progression, our
findings suggest SlOO as a good 'stand alone' prognostic marker for
overall survival in metastatic malignant melanoma. In conclusion,
we currently favour the use of traditional clinical criteria in assess-
ment of the prognosis of metastatic melanoma. Further clinical
testing of the above-listed markers is warranted in a multivariate
study, also taking into account traditional clinical criteria. As, in the
present study, SI00 did not achieve statistical independence upon
multivariate analysis, this marker is unlikely to provide any addit-
ional information that could be useful forthe management and prog-
nosis ofmetastatic melanoma patients.
REFERENCES
Atzpodien J, Lopez Hinninen E, Kirchner H, Franzke A, Korfer A, Volkenandt M,
Duensing S, Schomburg A, Chaitchik S and Poliwoda H (1995)
Chemoimmunotherapy ofadvanced malignant melanoma: sequential
administration ofsubcutaneous Interleukin-2 and Interferon-a after
intravenous dacarbazine, cisplatin, carmustine and Tamoxifen. EurJ Cancer
31A: 876-881
Cox DR (1972) Regression models and life-tables. JR Stat Soc [B] 34: 187-220
Dannies PS and Levine L (1969) Demonstration of subunits ofbeefbrain acidic
protein S-I00. Biochem Biophys Res Commun 37: 587-592
Fagnart OC, Sindic CJM and Laterre C (1988) Particle counting immunoassay of S-
100 protein in serum. Possible relevance in tumors and ischemic disorders of
the central nervous system. Clin Chem 34: 1387-1391
Gaynor R, Herschman HR, Irie R, Jones P, Morton D and Cochran A (1981) S100
protein: a marker for human malignant melanomas? Lancet 1: 869-871
Glass AG and Hoover RN (I1993) The emerging epidemic of melanoma and
squamous cell cancer. JAm MedAssoc 262: 2097-2100
Grin-Jorgensen CM, Rigel DS and Friedman RJ (1992) The worldwide incidence of
malignant melanoma. In Cutaneous Melanoma, Balch MB, Houghton AN,
Milton GW, Sober Al and Soong SJ (eds), pp. 27-39. JB Lippincott:
Philadelphia
© Cancer Research Campaign 1997 British Journal of Cancer (1997) 75(9), 1373-13761376 J Buer et al
Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J and Klingmiiller D (1995)
Clinical significance of serum S100 in metastatic malignant melanoma. EurJ
Cancer 31A: 1898-1902
Heimdal K, Hannisdal E and Gunderson S (1989) Metastatic malignant melanoma.
EurJ Cancer 25: 1219-1223
Isobe T, Ishioka N and Okuyama T (1981) Structural relation of two S-100 proteins
in bovine brain; subunit composition of S100a protein. Eur JBiochem 115:
469-474
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete
observations. JAm StatAssoc 53: 457-481
Karlsson M, Jungnelius U, Aamdal S, Boeryd B, Carstensen J and Kagedal B (1996)
Correlation of DNA ploidy and S-phase fraction with chemotherapeutic
response and survival in a randomized study ofdisseminated malignant
melanoma. Int J Cancer 65: 1-5
Koh HK (1991) Cutaneous melanoma. NEngl JMed 325: 171-182
Kunter U, Buer J, Probst M, Duensing S, Dallmann l, Grosse J, Kirchner H,
Schluepen EV, Volkenandt M, Ganser A and Atzpodien J (1996) Peripheral
blood tyrosinase messenger RNA detection and survival in malignant
melanoma. JNatl Cancer Inst 88: 590-594
Legha SS (1989) Current therapy for malignant melanoma. Sem Oncol 16:
34-44
Sirott MN, Bajorin DF, Wong GYN, Tao Y, Chapman PB, Templeton MA and
Houghton AN (1993) Prognostic factors in patients with metastatic malignant
melanoma. Cancer 72: 3091-3098
Smith H, Selby P, Southgate J, Pittman K, Bradley C and Blair GF (1991 ) Detection
of melanoma cells in peripheral blood by means of reverse transcriptase and
polymerase chain reaction. Lancet 338: 1227-1279
Trent JM, Meyskens FL, Salmon SE, Ryschon K, Leong SPL, Davis JR and McGee
DL (1990) Relation ofcytogenetic abnormalities and clinical outcome in
metastatic melanoma. NEngl J Med 322: 1508-151 1
Xerri L, Grob JJ, Battyani Z, Gouvemet J, Hassoun J and Bonerandi JJ
(1994) NM23 expression in metastasis of malignant melanoma is
predictive prognostic parameter correlated with survival. BrJ Cancer 70:
1224-1228
British Journal of Cancer (1997) 75(9), 1373-1376 © Cancer Research Campaign 1997